Avanos Medical, Inc. (AVNS)
NYSE: AVNS · Real-Time Price · USD
11.26
+0.13 (1.17%)
Dec 5, 2025, 4:00 PM EST - Market closed
Avanos Medical Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Avanos Medical.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Avanos Medical.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 0 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | May 7, 2024 |
| Keybanc | Keybanc | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jul 25, 2023 |
| Stifel | Stifel | Hold Reiterates $25 | Hold | Reiterates | $25 | +122.02% | Jun 21, 2023 |
| CL King | CL King | Strong Buy Initiates $31 | Strong Buy | Initiates | $31 | +175.31% | May 22, 2023 |
| Morgan Stanley | Morgan Stanley | Sell Maintains $28 → $26 | Sell | Maintains | $28 → $26 | +130.91% | May 4, 2023 |
Financial Forecast
Revenue This Year
708.90M
from 687.80M
Increased by 3.07%
Revenue Next Year
724.20M
from 708.90M
Increased by 2.16%
EPS This Year
0.92
from -8.53
EPS Next Year
0.97
from 0.92
Increased by 5.56%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 729.8M | 745.5M | |
| Avg | 708.9M | 724.2M | |
| Low | 681.1M | 695.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 6.1% | 5.2% | |
| Avg | 3.1% | 2.2% | |
| Low | -1.0% | -1.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.95 | 1.00 | |
| Avg | 0.92 | 0.97 | |
| Low | 0.88 | 0.93 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 8.7% | |
| Avg | - | 5.6% | |
| Low | - | 1.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.